An interventional study of Phacoemulsification combined with trabeculectomy and Phacoemulsificaiton combined with ab-externo trabeculotomy in Ophthalmopathy, Glaucoma and Glaucoma, Angle-Closure, sponsored by Assiut University. Completed at 1 site in Egypt. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-10-29.
Sponsored by Assiut University · Not applicable, Interventional, and Treatment
A prospective, randomized comparative study on adult patients with synechial angle closure glaucoma.
Patients were randomized into two groups: group A : patients will undergo two site phacoemulfication combined with trabeculectomy Group B with Phacoemulsification combined with ab-externo trabeculotomy. Preoperative assessments including full ophthalmic examination, anterior segment Optical Coherence Tomography (OCT) of the angle , endothelial cell count , visual fiend Perimetry and Biometry. Patients were followed up: first day, first week and every two months for 6 month. We will compare adverse effects and outcomes in both groups.
91 studies on the registry are indexed under Glaucoma, Angle-Closure; 17 are open to participants now.
This study's enrollment of 50 is below the median of 57 across 58 interventional studies indexed under Glaucoma, Angle-Closure.
Browse Glaucoma, Angle-Closure studies →Assiut University is the lead sponsor of 5,078 studies on the registry; 2,178 are open to participants now.
Of its 14 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Compared within Glaucoma, Angle-Closure, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Eye Diseases. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients with chronic angle closure glaucoma, with or without peripheral anterior synechiae, age more than 18
Exclusion Criteria:
Patients will undergo Two site phacoemulsification combined with trabeculectomy with Mitomycin C
Procedure: Phacoemulsification combined with trabeculectomy
Patients will undergo two phacoemulsification combined with deep sclerectomy and ab-externo trabeculotomy
Procedure: Phacoemulsificaiton combined with ab-externo trabeculotomy
Patients with chronic angle closure glaucoma assigned to this group will have fornex based trabeculectomy at superior limbus and then phacoemulsification via temporal incision
Patients with chronic angle closure glaucoma assigned to this group will have Deep Sclerectomy with ab externo trabeculotomy at superior limbus and then phacoemulsification via temporal incision
Absolute Success
Reduction of IOP more than 30% on no glaucoma drops
Time frame: 1,3,6 months
Visual outcome
Uncorrected visual acuity by Snellen's chart
Time frame: 1,3,6 month
Adverse events
all intraoperative and postoperative adverse events witt be recorded
Time frame: 1 week, 1 month, 3 months, 6 months
Plan to share: Yes — All of the individual participant data in the study , after completion after de-identification
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code
Time frame: after publication and for five years
Access criteria: Anyone who wants to access data
This study is completed, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.